GU Cancer ASCO 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / gu-cancer-asco-2024-highlights

Following the 2024 ASCO Annual Meeting, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates in genitourinary cancer.

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 1: EV-302: Patient-Reported Outcomes from EV+Pembro in mUC

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD
June 20th 2024

Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 2: The Role of ctDNA in Genitourinary Cancer

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD
June 20th 2024

Toni Choueiri, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in treatment paradigms for patients with genitourinary cancers.

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 3: KIM-1: Biomarker Analysis in IMmotion010 in RCC

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD
June 20th 2024

Focusing on renal cell carcinoma, the Oncology Brothers and Toni Choueiri, MD, discuss KIM-1, a biomarker analysis in IMmotion010.

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 4: Real-World Evidence from the IMDC

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD
June 20th 2024

Medical oncologists discuss how real-world evidence from the IMDC is informing treatment decisions in GU cancer.

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 5: PSMAfore: Health-Related QoL and Pain in Taxane-Naïve Patients with mCRPC

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD
June 20th 2024

Toni Choueiri, MD, and the Oncology Brothers discuss the PSMAfore study evaluating health-related quality of life and pain in taxane-naïve patients with metastatic castration-resistant prostate cancer.